Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under a joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. This deployment marks TechForce's first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
According to the press release, TechForce said the deployment completed the initial operational goals established under the companies' April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows, and other automation applications.
Nightfood views healthcare, life sciences, and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service (RaaS) platform. This strategic shift into laboratory automation could have significant implications for the pharmaceutical industry, where efficiency and precision are critical. Autonomous robots like LIM-E could streamline repetitive tasks, reduce human error, and accelerate research and development processes.
The deployment also highlights the growing trend of AI and robotics integration in life sciences. As drug development becomes increasingly complex, automation solutions that enhance workflow consistency and scalability are becoming essential. TechForce's entry into this space could offer cost-effective alternatives to traditional laboratory automation systems, potentially lowering barriers for smaller biotech firms.
For Nightfood Holdings, this milestone represents a diversification from its core hospitality focus into higher-margin, technology-driven sectors. The company's RaaS model could provide recurring revenue streams while addressing labor shortages and operational inefficiencies in pharmaceutical manufacturing. Investors should note that the full press release is available at https://ibn.fm/RFkfL.
Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, stands to benefit from enhanced laboratory automation. The collaboration may accelerate Oncotelic's research capabilities, particularly in addressing high-unmet-need cancers and rare pediatric indications. More information about Oncotelic is available at www.oncotelic.com.
TechForce Robotics, a subsidiary of Nightfood Holdings, develops and deploys autonomous robotic solutions through a vertically integrated platform combining proprietary robotics technology, real-world operating environments, and scalable manufacturing. Its solutions are delivered through a Robotics-as-a-Service model. For more information, visit www.techforcerobotics.com.
The successful deployment of LIM-E could pave the way for broader adoption of autonomous systems in pharmaceutical settings, potentially transforming laboratory workflows and manufacturing processes. As the industry continues to embrace automation, partnerships like this one may become increasingly common, driving innovation and efficiency across the life sciences sector.
